arrow
A

Anita Chudecka-Głaz

Pomeranian Medical University
H指数:22
被引数:2,151

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45

鲁卡帕利用于新诊断晚期卵巢癌的维持治疗:来自III期ATHENA-MONO/GOG-3020/ENGOT-ov45研究5年随访的 interim 总体生存期、无进展生存期及安全性数据

2025-10-180
OAAI
Safety and tolerability of durvalumab (D) plus carboplatin/paclitaxel (CP) plus bevacizumab (B) followed by D, B plus olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

在DUO-O III期试验中,评估 durvalumab (D) 联合 carboplatin/paclitaxel (CP) 及 bevacizumab (B) 诱导治疗后,再给予 D、B 联合 olaparib (O) 维持治疗(mtx)在无肿瘤 BRCA1/BRCA2 突变(non-tBRCAm)的新诊断晚期卵巢癌(AOC)患者中的安全性与耐受性。

2024-09-010
PRE
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer

ROSELLA的临床试验方案: relacorilant联合nab-紫杉醇与nab-紫杉醇单药治疗晚期铂类耐药卵巢癌的3期研究

2024-01-010
OAAI
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
2018-03-0132
OAAI